entertainment -WSS

entertainment

author：focus 2025-09-07 13:58:03 - browse：4415

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： The battle over the Brookhaven Landfill on Long Island

knowledge

WSS

Why we need to separate burnout from moral injury in health care

3 hurdles to bringing medical devices to the U.S. market

Why we need to separate burnout from moral injury in health care

Brain technologies pose threats that are all too real, experts warn

The battle over the Brookhaven Landfill on Long Island

The story of mRNA: From a loose idea to a tool that may help curb Covid

focus

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As health system earnings go up, health insurance stocks go down

Medical records are filled with copy

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Weight bias in eating disorder treatment complicated by new weight loss drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why drug prescriptions should include diagnoses

BioMarin wins approval for gene therapy to treat hemophilia A

Most antidepressants don't work on kids, teens, study finds

Wikipedia

Donald Trump's relentless attacks on special counsel Jack Smith

New guidelines on severe brain injury complicate already difficult decisions

Death of patient in Alzheimer’s trial raises question of possible risks

Warren pushes Witty on UnitedHealth's control over physicians

GSK’s asthma push continues as drug succeeds in Phase 3 trials

With FDA staff opposed to Sarepta therapy, top official intervened

Wikipedia

knowledge

knowledge

leisure time